These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 24533267)

  • 1. Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?
    Freitas-Junior LH; Chatelain E; Kim HA; Siqueira-Neto JL
    Int J Parasitol Drugs Drug Resist; 2012 Dec; 2():11-9. PubMed ID: 24533267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a target-free high-throughput screening platform for the discovery of antileishmanial compounds.
    Corman HN; Shoue DA; Norris-Mullins B; Melancon BJ; Morales MA; McDowell MA
    Int J Antimicrob Agents; 2019 Oct; 54(4):496-501. PubMed ID: 31323307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line.
    Jain SK; Sahu R; Walker LA; Tekwani BL
    J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective.
    Singh OP; Singh B; Chakravarty J; Sundar S
    Infect Dis Poverty; 2016 Mar; 5():19. PubMed ID: 26951132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds.
    Siqueira-Neto JL; Song OR; Oh H; Sohn JH; Yang G; Nam J; Jang J; Cechetto J; Lee CB; Moon S; Genovesio A; Chatelain E; Christophe T; Freitas-Junior LH
    PLoS Negl Trop Dis; 2010 May; 4(5):e675. PubMed ID: 20454559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visceral leishmaniasis: Revisiting current treatments and approaches for future discoveries.
    No JH
    Acta Trop; 2016 Mar; 155():113-23. PubMed ID: 26748356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Past and future of trypanosomatids high-throughput phenotypic screening.
    Dantas RF; Torres-Santos EC; Silva FP
    Mem Inst Oswaldo Cruz; 2022; 117():e210402. PubMed ID: 35293482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of new antileishmanial drugs--current knowledge and future prospects.
    Le Pape P
    J Enzyme Inhib Med Chem; 2008 Oct; 23(5):708-18. PubMed ID: 18671165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antileishmanial Drug Development: A Review of Modern Molecular Chemical Tools and Research Strategies.
    Mantravadi PK; Parthasarathy A; Kalesh K
    Curr Med Chem; 2021; 28(31):6337-6357. PubMed ID: 33238841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.
    Annang F; Pérez-Moreno G; García-Hernández R; Cordon-Obras C; Martín J; Tormo JR; Rodríguez L; de Pedro N; Gómez-Pérez V; Valente M; Reyes F; Genilloud O; Vicente F; Castanys S; Ruiz-Pérez LM; Navarro M; Gamarro F; González-Pacanowska D
    J Biomol Screen; 2015 Jan; 20(1):82-91. PubMed ID: 25332350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular targets and pathways for the treatment of visceral leishmaniasis.
    Jain V; Jain K
    Drug Discov Today; 2018 Jan; 23(1):161-170. PubMed ID: 28919438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history.
    Reimão JQ; Pita Pedro DP; Coelho AC
    Expert Opin Drug Discov; 2020 Jun; 15(6):647-658. PubMed ID: 32202449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Walking a tightrope: drug discovery in visceral leishmaniasis.
    Balaña-Fouce R; Pérez Pertejo MY; Domínguez-Asenjo B; Gutiérrez-Corbo C; Reguera RM
    Drug Discov Today; 2019 May; 24(5):1209-1216. PubMed ID: 30876846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of nanotechnology in treatment of leishmaniasis: A Review.
    Akbari M; Oryan A; Hatam G
    Acta Trop; 2017 Aug; 172():86-90. PubMed ID: 28460833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current approaches to discover marine antileishmanial natural products.
    Tempone AG; Martins de Oliveira C; Berlinck RG
    Planta Med; 2011 Apr; 77(6):572-85. PubMed ID: 21243582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal combinations of control strategies and cost-effective analysis for visceral leishmaniasis disease transmission.
    Biswas S; Subramanian A; ELMojtaba IM; Chattopadhyay J; Sarkar RR
    PLoS One; 2017; 12(2):e0172465. PubMed ID: 28222162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational drugs for visceral leishmaniasis.
    Sundar S; Chakravarty J
    Expert Opin Investig Drugs; 2015 Jan; 24(1):43-59. PubMed ID: 25409760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis.
    Reis TAR; Oliveira-da-Silva JA; Tavares GSV; Mendonça DVC; Freitas CS; Costa RR; Lage DP; Martins VT; Machado AS; Ramos FF; Silva AM; Ludolf F; Antinarelli LMR; Brito RCF; Chávez-Fumagalli MA; Humbert MV; Roatt BM; Coimbra ES; Coelho EAF
    Exp Parasitol; 2021 Feb; 221():108059. PubMed ID: 33338468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A chloroquinoline derivate presents effective in vitro and in vivo antileishmanial activity against Leishmania species that cause tegumentary and visceral leishmaniasis.
    Sousa JKT; Antinarelli LMR; Mendonça DVC; Lage DP; Tavares GSV; Dias DS; Ribeiro PAF; Ludolf F; Coelho VTS; Oliveira-da-Silva JA; Perin L; Oliveira BA; Alvarenga DF; Chávez-Fumagalli MA; Brandão GC; Nobre V; Pereira GR; Coimbra ES; Coelho EAF
    Parasitol Int; 2019 Dec; 73():101966. PubMed ID: 31362122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemisynthetic trifluralin analogues incorporated in liposomes for the treatment of leishmanial infections.
    Carvalheiro M; Esteves MA; Santos-Mateus D; Lopes RM; Rodrigues MA; Eleutério CV; Scoulica E; Santos-Gomes G; Cruz ME
    Eur J Pharm Biopharm; 2015 Jun; 93():346-52. PubMed ID: 25936854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.